Biodistribution, binding specificity and metabolism of [18F]fluoroethylflumazenil in rodents.
(2001) Nuclear Medicine and Biology — Vol. 28, n° 7, p. 809-814 (2001)
Files
document.pdf
Restricted Access - Adobe PDF
- 89.19 KB
Details
- Authors
- Abstract
- Pre-clinical studies were carried out in order to characterize in rodents the biodistribution, the binding specificity and the metabolism of [18F]Fluoroethylflumazenil ([18F]FEF), a potential candidate for in vivo imaging of the benzodiazepine receptors. In vivo competition with flumazenil indicates that [18F]FEF binds specifically to the benzodiazepine receptor in the brain. The accumulation of [18F]FEF was significantly lower than using [3H]Flumazenil. The rather low accumulation in the brain is due to a rapid metabolism of [18F]FEF in hydrophylic metabolites which cannot cross the blood brain barrier, and are rapidly eliminated in the urine. Inhibition of the metabolism by acetaminophen (chemically induced hepatitis) led to a significant increase of the radioactivity found in the circulating blood and in the brain, while these results were not observed using classical inhibitors of the cytochrome CYP450, cimetidine and ketoconazole.
- Affiliations
Citations
Levêque, P., Labar, D., & Gallez, B. (2001). Biodistribution, binding specificity and metabolism of [18F]fluoroethylflumazenil in rodents. Nuclear Medicine and Biology, 28(7), 809-814. https://doi.org/10.1016/S0969-8051(01)00251-7 (Original work published 2001)